During the NCCN Annual Conference, Ron Kline, MD, FAAP, from CMS’s Innovation Center, discussed the Center’s pilot Oncology Care Model.
A 3-year pilot program that rewarded oncologists for improving outcomes and efficiency—rather than administering drugs—significantly reduced overall costs without lowering quality of care.
Don’t let time constraints and large patient loads prevent you from providing a thorough well-woman visit. Are you covering all the bases?
Delivering patient-centered care and engaging in shared decision-making should be top priorities for oncologists responding to the current crisis in the quality of cancer care delivery, according to a recent Institution of Medicine report.
The American Society of Clinical Oncology (ASCO) today issued its second “Top 5” list of tests and treatments that are routinely used by oncologists despite a lack of evidence that they are cost effective or beneficial to patients.
ACOs can provide the structure, but it’s up to the stakeholders to establish mutually agreeable goals for this new care delivery model. Achieving these goals will require a different set of dialogues and conversations among stakeholders, and patients and their advocates must have seats at the table.
We examine efforts to correct cost inequities of oral anti-cancer agents through legislation, and we look at further efforts to reduce the cost of oral chemotherapy via cycle management and waste reduction.
Most community cancer centers are only beginning to measure quality of care and are struggling with the challenge of collecting data while adding services and keeping costs in check, concluded a recent survey by the Association of Community Cancer Centers (ACCC).
The Center for Medicare and Medicaid Services is inviting physicians to comment on a proposal to make individual physician payment data accessible to the public.
A group of cancer and other healthcare advocacy organizations applauded a provision in the Affordable Care Act that requires private insurers to cover the routine medical costs of patients participating in clinical trials. However, many of those patients will continue to face roadblocks to participating in trials unless the federal government provides clear guidance on implementation, the groups said in a recent letter.